Relapsed/Refractory Marginal Zone Lymphoma (MZL)
1 clinical trials · Condition
◉ Watch Relapsed/Refractory Marginal Zone Lymphoma (MZL)
| Record | Firm | Date |
|---|---|---|
| A Study of APG-3288 in Relapsed/Refractory Blood Cancers (NCT07424833) | Ascentage Pharma Group Inc. | 2026-08-01 |
Track Relapsed/Refractory Marginal Zone Lymphoma (MZL) automatically
Every clearance here is in the API, with alerts when new ones post.